Amgen beats Q1 earnings and revenue estimates, but shares dip as R&D spend rises

Amgen beat first-quarter expectations with adjusted EPS of $5.15 versus $4.80 consensus and revenue of $8.62 billion versus $8.59 billion, while product sales rose 4% and free cash flow increased to $1.5 billion from $1.0 billion a year earlier. The company’s fiscal 2026 EPS midpoint of $22.40 is slightly above the $22.30 analyst estimate, while revenue guidance is roughly in line at a $37.8 billion midpoint. Strength in Repatha, EVENITY, and UPLIZNA offset declines in Prolia and Enbrel, but shares still slipped 2%.

Analysis

AMGN’s print matters less as a one-quarter beat and more as evidence that the company is successfully re-rating from a single-patent-story biotech into a diversified cash-flow compounder. The key second-order effect is that accelerating volume in newer franchises can partially offset biosimilar erosion long enough for the market to underwrite the next leg of R&D optionality, especially MariTide, without compressing the multiple immediately. That said, the market is likely to keep discounting the headline until it sees whether newer growth categories can sustain enough mix shift to absorb the coming revenue hole from mature immunology and inflammation assets.

The main competitive implication is not just that competitors lose share; it is that Amgen is using cash generation to buy time in a biologics market where payer pressure and biosimilar penetration are increasingly forcing portfolio quality over size. If these growth brands continue compounding at double digits, suppliers and contract manufacturers tied to those products should see more stable utilization, while biosimilar players may find it harder to win on price alone if switching costs and physician inertia remain sticky. The flip side is that rising R&D intensity can become a problem if late-stage assets slip or if obesity differentiation is incremental rather than category-defining.

The contrarian read is that the pullback may be overdone relative to fundamentals, but not necessarily relative to biotech factor behavior: the stock likely needs proof that guidance is conservative rather than aspirational. Over the next 1-2 quarters, the critical catalyst is not EPS beats but whether growth momentum broadens beyond a few winners and whether management can keep free cash flow expanding while funding R&D. If operating margins hold and MariTide data de-risks, the market can re-rate AMGN as a de-risked cash compounder; if not, the stock stays trapped between value-stock support and biotech skepticism.

Key Decisions for Investors

• Go long AMGN on weakness for a 3-6 month horizon; the setup favors a multiple rerating if next quarter confirms that newer products can offset erosion faster than expected. Risk/reward is attractive because downside is cushioned by cash flow, while upside comes from sentiment improvement and obesity pipeline optionality.
• Sell out-of-the-money AMGN puts into earnings-related volatility over the next 30-60 days; premium should remain supported by the market’s uncertainty around guidance durability, while the fundamental downside appears limited unless pipeline data disappoints.
• Pair long AMGN / short a high-burn biotech basket over the next 1-2 quarters; AMGN has the balance sheet and FCF to self-fund growth, while weaker peers remain hostage to capital markets and pipeline execution.
• If you want event-driven exposure, buy AMGN calls into any MariTide-related clinical catalyst with a 6-12 month tenor; the skew is favorable because even modest obesity differentiation could expand the multiple, while the defined downside is the premium paid.
• Avoid chasing biosimilar-heavy names on this print; Amgen’s ability to absorb erosion through volume growth suggests the competitive moat is now portfolio breadth plus capital allocation, not just legacy franchise size.